secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2026-07-23T20:00:24+00:00
Accession:  0001323885-26-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago
--------------------------------------------------------------------------------

- Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).
- Net income $9.0M ($0.18 EPS) vs net loss of $0.13 per share in Q2 2025; adjusted EBITDA $27.3M (+78%).
- Gross margin 77.2%, up 269 bps YoY; income from operations $9.7M vs loss of $6.2M.
- Growth driven by cryoSPHERE MAX pain management probe, EnCompass clamp, AtriClip devices; international revenue $28.0M (+9.6%).
- Advancing BoxX-NoAF and LeAAPS clinical trials towards data readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/0001323885-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/atrc-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001323885-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer